EurekAlert!

Generic HIV treatment strategy could save nearly $1 billion annually but may be less effective

Replacing the combination of brand-name, antiretroviral drugs currently recommended for control of HIV infection with soon-to-be-available generic medications could save the U.S. health care system ...
Business Wire

Research and Markets: Countering Generic and Biosimilar Threats - Generics Currently Account for More Than 10% of All Drug Sales

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/89beda/countering_generic) has announced the addition of Cutting Edge ...
Health Affairs

Impact Of Risk Evaluation And Mitigation Strategies On Generic Approvals Of US Pharmaceutical Products

Risk evaluation and mitigation strategy (REMS) programs help ensure that the benefits of certain high-risk medications outweigh their risks. With the routine use of REMS programs, however, concerns ...
Nasdaq

Tevogen Advances Generics Strategy, Signs Letter of Intent to Evaluate Potential Acquisition of Apozeal Pharmaceutical

WARREN, N.J., March 05, 2026 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced that it has entered into a signed, non-exclusive, non-binding Letter ...
Business Wire

Research and Markets: Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/07fbd3/generic_growth_str) has announced the addition of the "Generic Growth ...
Pharm Exec

GLP-1 Patent Expiry & the Rise of Generics: Transforming the Drug Delivery Device Landscape & Procurement Strategy

Patent expiry across API, formulation, and device IP is expected to catalyze biosimilar competition, expanding access while compressing pricing across pharmaceutical and device value chains.
Seeking Alpha

Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative Medicines Transcript

Good morning, everyone, and welcome to our Viatris Investor event. I'm Bill Szablewski, Head of Capital Markets and Investor Relations. It's great to see everyone here in a full room today. Before we ...